ATE494905T1 - Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom - Google Patents

Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom

Info

Publication number
ATE494905T1
ATE494905T1 AT08013828T AT08013828T ATE494905T1 AT E494905 T1 ATE494905 T1 AT E494905T1 AT 08013828 T AT08013828 T AT 08013828T AT 08013828 T AT08013828 T AT 08013828T AT E494905 T1 ATE494905 T1 AT E494905T1
Authority
AT
Austria
Prior art keywords
product
cancer
suppressor gene
tumor suppressor
vaccine containing
Prior art date
Application number
AT08013828T
Other languages
English (en)
Inventor
Tadanori Mayumi
Haruo Sugiyama
Yoshiyuki Ohsugi
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadanori Mayumi
Haruo Sugiyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Tadanori Mayumi, Haruo Sugiyama filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE494905T1 publication Critical patent/ATE494905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08013828T 2001-06-29 2002-06-28 Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom ATE494905T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001199449 2001-06-29

Publications (1)

Publication Number Publication Date
ATE494905T1 true ATE494905T1 (de) 2011-01-15

Family

ID=19036745

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08013828T ATE494905T1 (de) 2001-06-29 2002-06-28 Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom

Country Status (9)

Country Link
US (2) US20060165708A1 (de)
EP (2) EP2014300B1 (de)
JP (2) JP4229832B2 (de)
CN (1) CN1320923C (de)
AT (1) ATE494905T1 (de)
CA (1) CA2451846A1 (de)
DE (1) DE60238958D1 (de)
HK (1) HK1064589A1 (de)
WO (1) WO2003002142A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2478446T3 (es) 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
DE602004027655D1 (de) * 2003-11-03 2010-07-22 Yissum Res Dev Co Verfahren zur auswahl von kationischen oder anionischen liposomen zur behandlung einer schleimhautmembran und diese enthaltendes set
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
EP1657250A1 (de) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A*01 bindendes T-Zell-Epitop von WT1
AU2006304573B2 (en) * 2005-10-17 2012-05-24 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
JP5002749B2 (ja) * 2006-03-22 2012-08-15 富士フイルム株式会社 癌抑制剤
EP3117836A1 (de) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verwendungen davon
JP2008031063A (ja) * 2006-07-27 2008-02-14 Fujifilm Corp 癌抑制剤
CN104774910B (zh) 2007-02-27 2018-04-10 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
CA2686840A1 (en) * 2007-02-28 2008-09-04 National University Corporation Hokkaido University Liposome for induction of cell-mediated immunity
EP3173480A3 (de) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Krebs-antigen-spezifisches t-zell-rezeptorgen, durch das gen codiertes peptid und verwendung davon
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
ITTO20070401A1 (it) * 2007-06-07 2008-12-08 Univ Degli Studi Torino Vaccino anti-tumorale
ES2712505T3 (es) 2008-04-17 2019-05-13 Pds Biotechnology Corp Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos
ES2849187T3 (es) 2010-10-05 2021-08-16 Int Inst Cancer Immunology Inc Método para activar células T auxiliares
WO2012105224A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 ワクチン・アジュバント
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ１ペプチド及びその使用方法
US8562681B2 (en) 2012-01-31 2013-10-22 Styker Spine Laminoplasty implant, method and instrumentation
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
JP6530192B2 (ja) 2012-12-17 2019-06-12 大塚製薬株式会社 ヘルパーｔ細胞の活性化方法
CN116789792A (zh) 2013-01-15 2023-09-22 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
DE102015201207B4 (de) 2014-06-24 2019-02-21 Sms Group Gmbh Viersattelpressenwerkzeug und Schmiedepresse sowie Verfahren zum Schmieden eines Werkstücks
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2023212095A1 (en) * 2022-04-27 2023-11-02 The Regents Of The University Of California Molecules that enhance extracellular vesicle release

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US104627A (en) 1870-06-21 Improvement in churn-power
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
CA2349442C (en) * 1998-09-30 2012-12-04 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Also Published As

Publication number Publication date
EP1410804A4 (de) 2007-10-24
JP4229832B2 (ja) 2009-02-25
US20060165708A1 (en) 2006-07-27
EP1410804A1 (de) 2004-04-21
WO2003002142A8 (en) 2003-12-11
CA2451846A1 (en) 2003-01-09
EP2014300B1 (de) 2011-01-12
US20090098197A1 (en) 2009-04-16
DE60238958D1 (de) 2011-02-24
JP2009079054A (ja) 2009-04-16
JPWO2003002142A1 (ja) 2004-10-14
EP2014300A1 (de) 2009-01-14
CN1520311A (zh) 2004-08-11
HK1064589A1 (en) 2005-02-04
CN1320923C (zh) 2007-06-13
WO2003002142A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE494905T1 (de) Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
NO20015073L (no) Vaksiner
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
GEP20063895B (en) Platinum derivative pharmaceutical formulations
CY1109045T1 (el) Ρετινοειδη για τη θεραπεια του εμφυσηματος
DK0741716T3 (da) Delta12,13-Iso-taxolanaloger, antineoplastisk anvendelse og farmaceutiske præparater indeholdende dem
ATE297750T1 (de) Verwendung von hsp70 protein
DE60008399D1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
MX2020009150A (es) Anfifilos de cpg y usos de los mismos.
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
EP1004319A4 (de) Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten
DE60117247D1 (de) Phosphoramidat-prodrugs
DK0655926T3 (da) Ny sonde til tumordiagnose eller tumorterapi
IL165086A (en) Pyridyl cyanoguanidines, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
DE69918961D1 (de) Verbesserte inhalationspräparate
MXPA04001912A (es) Aminobenzofenonas novedosas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties